ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN
But 'Unique Side Effects' A Concern
Executive Summary
Lorbrena is approved as a second-line treatment for ALK-positive NSCLC but Pfizer believes data from the first-line Phase III CROWN study makes the drug a serious competitor to standard of care Alecensa in the first-line setting.
You may also be interested in...
Pfizer Embraces Biotech-Like Speed To Advance BCMA Bispecific
Chris Boshoff, Pfizer Oncology chief development officer, said lessons from the rapid pace of the company’s COVID-19 vaccine program are being applied to elranatamab and other cancer therapies.
Keeping Track: Chiesi Breathes Easier With Bronchitol Approval; Submissions Aplenty From GSK, Pfizer, AZ, AbbVie
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Need a specific report? 1000+ reports available
Buy Reports